DNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapy - PubMed
6 hours ago
- #Lipid Nanoparticles
- #CD8+ T Cells
- #Cancer Immunotherapy
- DNA delivered by lipid nanoparticles (DNA-LNPs) activates STING and AIM2 pathways to enhance antitumor immune responses.
- DNA-LNP treatment induces cytokine production and recruits CD8+ T cells to the tumor microenvironment, leading to potent antitumor effects.
- The study demonstrates prolonged animal survival across multiple cancer models, including hepatocellular carcinoma, acute myeloid leukemia, and melanoma.
- DNA-LNPs synergize with anti-PD-L1 therapy, improving outcomes in both ICI-responsive and ICI-resistant tumors.
- Empty LNPs do not trigger significant immune responses, highlighting the role of cytosolic DNA-sensing pathways in the observed effects.